Assembly Biosciences to Present at the Jefferies London Healthcare Conference
November 08 2017 - 7:00AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage
biotechnology company advancing a new class of oral therapeutics
for the treatment of hepatitis B virus (HBV) infection and novel
oral live biotherapeutics for disorders associated with the
microbiome, today announced that Derek Small, chief executive
officer, will present an overview of the company on Wednesday,
November 15th at 11:20 a.m. GMT at the Jefferies Healthcare
Conference in London.
A live audio webcast and archive of the
presentation will be available in the Events and Presentations
section of the Company’s website at assemblybio.com.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage public biotechnology company developing
two innovative platform programs: an HBV program advancing a new
class of oral therapeutics for the treatment of hepatitis B virus
(HBV) infection and a microbiome program developing novel oral live
biotherapeutics designed to address diseases associated with the
microbiome. Assembly’s HBV program is advancing multiple drug
candidates with the aim of increasing cure rates in patients with
chronic HBV. The company's microbiome program consists of a fully
integrated platform that includes a robust strain identification
and selection process, methods for strain isolation and growth
under current Good Manufacturing Practices and a patent-pending
delivery system, GEMICEL®, which allows for targeted oral delivery
of live biologic and conventional therapies to the lower
gastrointestinal tract. Assembly is developing a robust pipeline of
product candidates in multiple disease indications. For more
information, visit assemblybio.com.
Forward-Looking Statement The information in
this press release contains forward-looking statements regarding
future events, including statements about the clinical and
therapeutic potential of Assembly’s development programs. Certain
forward-looking statements may be identified by reference to a
future period or periods or by use of forward-looking terminology
such as “designed” or "developing." Assembly intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. More information about the risks and uncertainties
faced by Assembly are more fully detailed under the heading "Risk
Factors" in Assembly’s Annual Report on Form 10-K for the year
ended December 31, 2016, and Quarterly Report on Form 10-Q for the
quarter ending September 30, 2017 filed with the Securities and
Exchange Commission. Except as required by law, Assembly assumes no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
ContactsAssembly Biosciences, Inc.
Investors: Lauren Glaser
(415) 521-3828lglaser@assemblybio.com
Media:Barbara Lindheim(212) 584-2276barbara@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2024 to May 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From May 2023 to May 2024